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Purpose: To maximize effective use of mydriatic drugs through comparing the pupillary dilation effects between 
1% tropicamide and 2.5% phenylephrine.
Methods: Fifty people requiring pupillary dilation were divided into 3 groups. Group 1 was treated with one drop of 
1% tropicamide in the right eye and one drop of 2.5% phenylephrine in the left eye. Group 2 was treated twice 
during a 5-minute interval with 1% tropicamide in the right eye. Group 3 was treated twice during a 5-minute 
interval with 2.5% phenylephrine in the right eye. Groups 2 and 3 were treated with 2.5% phenylephrine and 1% 
tropicamide in the left eye, administered during a 5-minute interval. The pupillary size was measured in all groups 
for 40 minutes following eye drops administration. 
Results: The mean patient age was 15.7 years. Group 1 included 10 patients, and groups 2 and 3 included 20 
patients each. Eight patients in group 1 and 16 patients in group 2 developed a larger right pupil. Fourteen patients 
in group 3 developed a larger left pupil. 
Conclusions: Our study showed that 1% tropicamide, with its parasympathetic antagonistic mechanism of action, 
was more effective at inducing pupillary dilation than 2.5% phenylephrine, and the combination of 1% tropicamide 
and 2.5% phenylephrine was more effective than multiple drops of single eye drops.
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Pupillary dilation is an essential component of ophthal-
mologic tests and treatments. Magnitude of dilation depends 
on the sphincter muscle of the pupil, controlled by parasym-
pathetic nerves, and on the dilator muscle of the pupil, 
controlled by sympathetic nerves.
1,2 The parasympathetic 
antagonist tropicamide and the sympathetic agonist phenyle-
phrine are frequently used to achieve dilation in the clinical 
setting.
In studying these two eye drops, Siderov and Nurse
3 reported 
that twice the normal dose of 0.5% tropicamide achieved a 
larger pupil size than a single dose. Krumholz et al.
4 reported 
no significant difference in pupil size among 3 different eye 
drops regimens: 0.5% tropicamide and 2.5% phenylephrine, 
0.5% tropicamide and 1.25% phenylephrine, and 0.25% 
tropicamide and 1.25% phenylephrine. Since diluted eye 
drops may still have clinically significant pupillary dilation 
effect, they may still be useful when combined with eye 
drops having a different mechanism of action.
The current study evaluated the mydriatic effect of different 
types of eye drops and investigated their efficacy through 
delivering multiple drops of a single drug and through com-
bining eye drops with different mechanisms of action.
Materials and Methods
We studied 100 eyes in 50 patients requiring pupillary 
dilation as part of their visit to the Department of Ophthal-
mology at Dongsan Medical Center, Keimyung University, 
between July and September 2007. Given the possible side 
effects of phenylephrine, patients with a history of cardiac 
disease, high blood pressure, ophthalmologic surgery possibly 
affecting the pupil size, eye trauma, diabetes, or more than 
0.25 mm of anisocoria before pupillary dilation were excluded 
from the study. 
The subjects were divided into 3 groups. Group 1 received 
one drop of 1% tropicamide (Mydriacyl
®, Alcon Co.,USA) 
in the right eye and one drop of 2.5% phenylephrine (Mydfrin
®, 
Alcon Co., USA) in the left eye. Group 2 received two drops 
of 1% tropicamide in the right eye, delivered 5 minutes apart, 
and one drop each of 2.5% phenylephrine and 1% tropicamide 
in the left eye, delivered 5 minutes apart. Group 3 received JH Park, et al. COMPARISON OF MYDRIATIC EFFECT
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Table 1. The mean pupillary diameter before instilling the mydriatics (mean±SD, mm)
Group 1 (n=10) Group 2 (n=20) Group 3 (n=20)
Subgroup A 4.46±0.26 4.15±0.47 3.82±0.41
Subgroup B 4.07±0.56 3.97±0.74 4.17±0.66
Total 4.26±0.41 4.06±0.60   4.0±0.49
Table 2. The mean time to reach maximal mydriasis after instilling the mydriatics (mean±SD, min)
Group 1 (n=10) Group 2 (n=20) Group 3 (n=20)
Right eye 37.0±3.50 36.45±4.47 38.75±2.22
Left eye 37.5±2.64   37.6±4.16   39.0±2.05
Fig. 1. The eye where the maximal pupillary diameter was signi-
ficantly larger.
two drops of 2.5% phenylephrine in the right eye and one 
drop each of 2.5% phenylephrine and 1% tropicamide in the 
left eye, delivered 5 minutes apart. To monitor mydriatic 
effect by age, each group was divided into a subgroup less 
than 14 years of age (A) and a subgroup greater than 15 years 
of age (B). There were 10 patients in group 1, and 20 patients 
each in groups 2 and 3. Group 1 included 5 patients in both 
the subgroup A and B, group 2 included 10 patients in both 
the subgroup A and B, and group 3 included 10 patients in 
both the subgroup A and B.
To prevent the dilution of the eye drops through tearing, 
0.5% proparacaine hydrochloride (Alcaine
®, Alcon Co., USA) 
was delivered to each eye 5 minutes before administering the 
dilating drugs. All eye drops were placed within the con-
junctival sac of the lower eyelid, and patients were directed 
to close their eyes approximately 1 minute after drop delivery 
to prevent loss of medication through the punctum in the 
conjunctival sac.
The pupil size was photographed by a single evaluator 
using a Zeiss FF 450 camera (Carl Zeiss Meditec, Jena, 
Germany) before the use of eye drops and at 5, 10, 15, 18, 21, 
24, 27, 30, 35, and 40 minute after eye drops administration. 
For calculating pupil size, the VISUPAC program was used. 
Three repeated measurements were taken within an interval 
of a few seconds at each time point, and the mean value of the 
maximum horizontal diameter and the maximum vertical 
diameter of the pupil was recorded as the pupil size. Through 
applying built-in illumination grade II and flash 17, the 
measurement conditions for all test subjects were the same. 
Pupil size greater than 6 mm was considered to be clinically 
effective for ophthalmological testing. A maximum pupil size 
less than 6.0 mm was regarded as ineffective pupillary 
dilation.
5,6
For statistical analysis, SPSS 12.0 was used to perform 
Wilcoxon signed ranks test. Informed consent was acquired 
from all patients using a form approved by the Institutional 
Review Board of the above medical center.
Results
Patient age ranged from 3 years to 41 years, with a mean of 
15.7 years. Thirty patients were male, and 20 patients were 
female. The mean pupil sizes before eye drops administration 
were 4.26±0.41 mm, 4.06±0.6 mm, and 4.0±0.49 mm in 
groups 1, 2, and 3, respectively (Table 1). The maximum 
pupil size was defined as the maximum pupil size recorded 
during the 40 minutes following eye drops administration, 
the time needed to reach the maximum pupil size was similar 
in all groups examined (Table 2). In 8 of the 10 patients in 
group 1, the maximum pupil size was larger in the 1.0% 
tropicamide eye compared to the 2.5% phenylephrine eye 
(p=0.016). Sixteen patients in group 2 had a larger pupil in 
the two-fold 1.0% tropicamide eye than in the combined 2.5% 
phenylephrine and 1% tropicamide eye (p=0.081). Fourteen 
patients in group 3 had a larger pupil in the combined 2.5% 
phenylephrine and 1% tropicamide eye than in the two-fold 
2.5% phenylephrine eye (p=0.009). Figure 1 compares the 
maximum pupil sizes among the groups. No significant 
difference was found on comparison of the subgroup A and B 
within the 3 groups.
Seven eyes achieved a maximum pupil size less than 6.0 
mm: 3 eyes in group 2 (B), 2 eyes in group 3 (A), 1 eye in 
group 1 (B), and 1 eye in group 2 (A). One patient in group 2 
(B) experienced pupil diameter less than 6.0 mm in both Korean J Ophthalmol Vol.23, No.1, 2009
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eyes. Investigation demonstrated that this patient was wearing 
soft contact lenses in both eyes at the time of eye drops 
administration. This situation did not confound the statistical 
analysis.
Discussion
Tropicamide 1.0% and phenylephrine 2.5% eye drops are 
frequently used for the purpose of cycloplegic refraction, for 
fundus examination and photocoagulation, and for preventing 
the formation of posterior iris synechiae in uveitis. Dilation is 
also essential in preparation for several intraocular procedures, 
such as cataract extraction. Phenylephrine is a sympathetic 
agonist that shows mydriatic effect through direct action on 
sympathetic nerve receptors located on the pupillary dilator 
muscle of the iris. Phenylephrine rarely causes complications 
in the cardiovascular and autonomic nervous system.
7,8
We undertook this study to determine whether tropicamide, 
with a different mydriatic mechanism than phenylephrine, is 
capable of achieving enough pupillary dilation as an alternative 
eye drops.
Twa et al
9 and Pop et al
10 used a computer program to 
determine pupil size after photographing the anterior segment. 
This proved to be a precise and economical test method with 
higher repeatability than pupil measurement using the Colvard 
pupillometer or ruler. The current study also measured pupil 
size using photographs of the anterior segment.
Jung and Kim
11 measured the pupil size every 5 minutes 
for 90 minutes after treatment with 1.0% tropicamide and 
2.5% phenylephrine to compare pupillary dilation in patients 
with diabetic retinopathy. They reported that larger maximum 
pupil size was achieved through using 2.5% phenylephrine. 
This suggests a reduced effect of anticholinergic mydriatic 
drugs as a result of the neuropathy of the sympathetic inner-
vation caused by the derangements in the sympathetic nervous 
system. The current study compared the pupillary dilation 
effects of two different types of eye drops in a normal popu-
lation, regardless of age. We found larger maximum pupil 
size in eyes administered 1.0% tropicamide.
In 16 patients in group 2, we found that the pupil size of the 
eye treated with multiple drops of 1.0% tropicamide was 
larger than that of the eye treated with combined use of 2.5% 
phenylephrine and 1% tropicamide. It is difficult to conclude 
that multiple drops of 1.0% tropicamide are more effective 
than combination eye drops due to the lack of a statistically 
significant difference between the groups.
Smith and Smith
12 reported that eye drops with anticho-
linergic effect block the parasympathetic nervous system and 
paralyze contraction of the sphincter muscle of the pupil, 
leading to an unmasking of the sympathetic nervous system 
effect on the pupillary dilator muscle. In the current study, the 
combined use of 2.5% phenylephrine and 1% tropicamide in 
group 3 resulted in larger pupil size compared to two-fold 
treatment with 2.5% phenylephrine. Therefore, it is believed 
that combined use of 1% tropicamide and 2.5% phenylephrine 
was more effective than use of 2.5% phenylephrine alone.
Concerning limitations of the current study, there were 
statistically significant differences among the 3 groups, but 
the differences were mostly among patients that achieved a 
pupil size larger than 6.0 mm. This is an acceptable size for 
conducting general fundus examination. Therefore, the 
differences were not significant from a clinical perspective. 
Furthermore, since the study population was small, a statisti-
cally significant analysis could not be made when analyzing 
mydriatic effect by age. The current study followed the pupil 
size for 40 minutes after eye drops administration. Future 
complementary studies will need to consider patients that 
show a delayed medication effect beyond 40 minutes.
In summary, 1.0% tropicamide eye drops showed better 
mydriatic effect than 2.5% phenylephrine eye drops, and 
combination 1% tropicamide and 2.5% phenylephrine were 
found to be superior to multiple drops of 2.5% pheny-
lephrine in achieving pupillary dilation. Although combination 
eye drops were found to be inferior to multiple drops con-
taining 1% tropicamide, the difference between the two 
groups was not statistically significant. Nevertheless, it is 
believed that combination eye drops will produce a better 
outcome in enhancing the mydriatic effect than multiple 
drops of single eye drops.
References
 1. Lee YI, Kim JS, Nam KR. The pupillary dilatation effect of 
phenylephrine 2.5% versus 10% in patients with diabetes. J 
Korean Ophthalmol Soc 1997;38:1655-9.
 2. Loewenfeld IE, Newsome DA. Iris mechanics. I. Influence 
of pupil size on dynamics of pupillary movements. Am J 
Ophthalmol 1971;71:347-62.
 3. Siderov J, Nurse S. The mydriatic effect of multiple doses of 
tropicamide. Optom Vis Sci 2005;82:955-8.
 4. Krumholz DM, Portello JK, Rosenfield M, Rosenbaum JD. A 
combination solution for routine pupillary dilation. Optometry 
2006;77:350-3.
 5. Blansett DK. Dilation of the pupil. In: Bartlett JD, Jannus SD. 
Clinical Ocular Pharmacology, 4th ed. Boston: Butterworth, 
2001:405-11.
 6. Feldman JB. Mydriatics a clinical observation. Arch ophthalmol 
1949;41:42-59.
 7. Fraunfelder FT, Scafiti AF. Possible adverse effects from topical 
ocular 10% phenylephrine. Am J ophthalmol 1978;85:447-53.
 8. Leopold IH. The phenylephrine saga -- a drug dilemma. Am J 
ophthalmol 1978;85:572-4.
 9. Twa MD, Bailey MD, Hayes J, Bullimore M. Estimation of 
pupil size by digital photograph. J Cataract Refract Surg 2004; 
30:381-9.
10. Pop M, Payette Y, Santoriello E. Comparison of the pupil card 
and pupillometer in measuring pupil size. J Cataract Refract 
Surg 2002;28:283-8.
11. Jung BH, Kim SY. Pupillary dilation with mydriatics in diabetic 
retinopathy. J Korean Ophthalmol Soc 1992;33:495-500.
12. Smith SA, Smith SE. Evidence for a neuropathic aetiology in the 
small pupil of diabetes mellitus. Br J Ophthalmol 1983;67: 
89-93.